Peptide Knowledge Base · Metabolic
Adipotide (FTPP): what it is, what the evidence says, and its real status
A pro-apoptotic peptide that targets the blood supply of fat tissue, striking animal fat loss, but documented kidney toxicity.
Short version: a high-risk research peptide that killed fat-tissue blood vessels in animals, and damaged kidneys doing it. Education and caution only; we capture the query, never the sale.
Can you actually get it?
Plain-English verdict: Education only.
Regulatory status: Research-only · Education only.
Not offered, high-risk, education only. Adipotide is a preclinical pro-apoptotic peptide with documented renal toxicity in animal studies. It is not FDA-approved and not safe to obtain; we provide caution-first education only.
How does Adipotide (FTPP) work?
A peptide that triggers apoptosis in the vasculature feeding white adipose tissue, effectively starving fat stores.
What it does — and what it does not do
What it does: Produced striking fat loss in animal models.
What it does not do: It is not proven or safe in humans, animal studies showed kidney toxicity, and it is not available.
How honest is the evidence?
Evidence grade D — preclinical only; animal renal toxicity documented. Read our grading methodology for what each grade means.
What we still don't know: No credible human safety or efficacy data; renal toxicity is the headline risk.
WADA status: Not prohibited.
How it is taken
Not offered; education only.
Who should not take it
Documented renal toxicity in animals; not characterized or safe for human use.
Sources
Barnhart et al., adipotide preclinical (Sci Transl Med 2011)
Compounded medications are not FDA-approved. We keep two signals separate and never collapse them: whether you can get something, and what the rule currently says. See the live FDA Peptide Tracker or the knowledge base.
Last reviewed 2026-08-11 · Peptós.LIFE · Not medical advice.